Rectal Specimens collection and processing 41
Rectal secretions and rectal biopsies are collected with a proctoscope in place. Rectal 42 secretions are collected using two sponges (Merocel®, Medtronic) pre-moistened with 43 50 µL of PBS which are inserted in the rectal cavity (one at the time), left in contact to 44 the mucosal surface for 5 minutes and then transferred to the top chamber of the 45 spin-X tube filter 0.22 µm (Costar) containing 300 µL of protease inhibitor solution 46 (Calbiochem). Rectal secretions are extracted from the chamber by centrifugation and 47 stored at -80ºC. Rectal biopsies (10 punches) are collected using a Sarrat disposable 48 forceps (STE1500, Stericom) and placed in a tube containing supplemented R10. 49
Nine out of 10 rectal punch biopsies are digested using collagenase type II (Sigma) 50 and used fresh for cytometric analysis. One punch biopsy is stored in Cryomatrix 51
(ThermoScientific) at -150ºC for future analysis. 52 53
Saliva collection and processing 54
Participants are instructed to refrain from eating for 2h and drinking for 30 min prior to 55 saliva collection. Two sponges (Salivette®, Sarstedt) (one at the time) are inserted at 56 one side of the mouth (close to the parotid duct gland) for 5 min and then removed, 57 placed into a tube and kept on ice. Saliva is extracted from the sponges by 58 centrifugation, diluted two fold using protease inhibitor solution (Calbiochem) and 59 stored at -80ºC. 60
LABORATORY MEASUREMENTS 62

Cellular Immune Activation 63
Multicolor flow cytometric analysis are performed on mononuclear cells isolated from 64 blood, cervix and rectum and stained using pre-determined concentrations of the 65 
Measurement of Cytokines and Chemokines Concentrations 110
Electro-chemiluminescence U-Plex system (Meso Scale Discovery) is used to 111 measure the concentration of 14 cytokines (IL-1α, IL-1β, IL-6, IL-8, IL-10, IL-17A, 112
IFNγ, GM-CSF, IP-10, MIP-1α, MIP-1β, MIP-3α, TNF-α and IL-4). All samples are run 113 in duplicate following the manufactures' instructions. 114
115
STORAGE OF BIOLOGICAL SAMPLES 116
Biological samples are stored at KAVI-ICR, and the University of Toronto. Ancillary 117 studies not described at KAVI-VZV-001 protocol will be subjected to analysis by the 118 ethics boards and performed only upon their approval and only for samples whose 119 Varicella-Zoster Virus (VZV), Herpes Virus-2 (HSV-2), Cytomagalovirus (CMV), Epstein Barr (EBV) at KAVI-VZV-001 cohort c) Acceptability and feasibility of mucosal sampling at KAVI-VZV-001 cohort Pre-screening sections adopted during recruitment phase promotes participants' awarness about the study objectives, procedures and their rights reducing the stress associated with some of the sampling procedures and promoting a good retention rate in the study Acceptability and feasibility of mucosal sampling assessed by questionnaire and participant compliance to the study visits d) Association between Nugent scoring (used for bacterial vaginosis -BV -diagnostic), proinflammatory cytokine signature, cellular immune activation and microbiome A portion of our study cohort changes their BV status during the study and we hypothesize that this change is associated with changes in pro-inflammatory cytokine, cellular immune activation and microbiome signatures
Comparison between changes in BV nugent score and changes in pro-inflammatory cytokine, cellular immune activation and microbiome signatures (such as Gardnerella, Prevotella, Mobiluncus, Sneathia sp and Lactobacillus sp) 
